Exscientia's artificial intelligence-based drug discovery engine is still largely unproven, but that hasn't stopped the company raking in funding from investors keen to back its platform.
Pairaudeau joins Exscientia at a fertile time for the UK biotech, which specialises in applying artificial intelligence to the drug discovery process and reckons its approach can carve up to 75% ...
Impressive news from a high-profile business partner was a major reason for the stock price pop experienced by SoundHound AI ( SOUN 7.14%) on Thursday. The artificial intelligence (AI) company was up ...